The National Guidelines for the Diagnosis and Treatment of Toxoplasmosis in Hematopoietic Stem Cell Transplant Recipients have been developed as part of ToxoReTREAT, a project led by the Institute for Medical Research. The document provides healthcare professionals with a practical framework for a standardized approach to clinical care.
The guidelines integrate findings from research conducted in Serbia, the extensive experience of the Institute’s National Reference Laboratory for Toxoplasmosis, and recommendations from the Ninth European Conference on Infections in Leukaemia (ECIL 9). The recommendations have been adapted to the Serbian healthcare system, taking into account the organization of diagnostic services and the availability of laboratory testing and medicines.
Four clinical algorithms provide guidance on risk assessment, screening and monitoring, management following the detection of T. gondii DNA in peripheral blood by qPCR, and the evaluation and management of patients with suspected toxoplasmic disease. The document also addresses specific considerations for pediatric patients and recipients of autologous hematopoietic stem cell transplants.
The guidelines are intended for transplant teams, hematologists, pediatric hematologists and oncologists, infectious disease specialists, medical microbiologists, parasitologists, and other healthcare professionals involved in the care of this patient population.
The authors are Dr. Tijana Štajner, Dr. Olivera Lijeskić, and Dr. Jelena Srbljanović of the Institute for Medical Research, and Dr. Borko Gobeljić of the Mother and Child Health Care Institute of Serbia “Dr. Vukan Čupić.” The publication was reviewed by Professor Dragana Vujić.
ToxoReTREAT is funded by the Science Fund of the Republic of Serbia through its PRISMA program. The guidelines represent one of the project’s contributions to translating research findings into clinical practice.